





Di Zhang¹, Jaejoon Song¹, Yong Ma¹, Sai Dharmarajan¹, Hana Lee¹, Rongmei Zhang¹, Tae Hyun Jung¹, Bingqi Han², Mark Levenson¹

¹Division of Biometrics VII, Office of Biostatistics, Center for Drug Evaluation and Research, FDA, ²George Washington University

Introduction

Background

- In post-market drug safety surveillance, machine learning (ML) has been used to support regulatory decision making.
- ML was used in prediction and causal inference problems.

Overview of Methods


- Supervised versus Unsupervised Learning
 - o Supervised: CART, penalized regression, Bayesian additive regression tree (BART), random forest (RF), boosting, support vector machine (SVM) o Unsupervised: clustering
- Super Learner (SL)
 - o Utilize multiple ML algorithms
- Natural Language Processing (NLP) o Rule-based

Variable Ascertainment

GOAL: ascertain missing values for critical variables, such as age, in the FDA Adverse Event Reporting System (FAERS) database

METHOD: a rule-based NLP tool was developed to impute the missing age based on the unstructured free-text narratives

FINDING: high performance of this NLP tool with sensitivity of 0.99, specificity of 0.93, and PPV of 0.82



Biostatistical Contributions to the Use of Machine Learning in Regulatory Science



Health Outcome **Identification (HOI)**

GOAL: to improve algorithms to identify health outcomes in FDA Sentinel system

METHOD: applied various ML methods to classify anaphylaxis outcome based on claim-derived covariates, and EHR-derived covariates using NLP rule-based approaches

FINDING: combination use of Bayesian additive regression trees and NLP approaches improved the performance of the algorithm compared to NLP approaches only

CHALLENGE: limited data with known class labels available for training ML models, especially for rare safety outcomes

EXTENSION: determine the optimal training data size for imbalanced data applying ML methods for HOI, using a model-based method and a learning curve method

Drug Utilization Pat

GOAL: to explore pharmacy dispensing data to provide

METHOD: developed tool, geoMapr, to analyze prop prescription drug dispensing and applied in PHAST PI

- Decision tree-based ensemble algorithms to explore geographical factors associated with prescription dispensing
- Clustering for discovery of temporal patterns

FINDING: ML helps illustrate common trajectories of prescription change among geographic areas, and identify important factors contributed for the trajectory over time.

	 	-

Risk Factor Identification

GOAL: to understand factors driving opioid prescribing using National Ambulatory Medical Care Survey (NAMCS) data, which aims to reduce preventable harm from potentially inappropriate opioid prescriptions METHOD: LASSO penalized logistic regression, RF and SVM FINDING: the identified risk factors (e.g., patients with arthritis were more likely prescribed with opioid) can inform inappropriate opioid prescribing	GO lear road effe wor NE base SL i obse SL i obse SL i		
	P P P in a -0.05-		
tern Discovery			
ide insights for oversight of drug utilization prietary, nationally projected data for	-0.20-		
Photomorphic Photo			
Cluster: 2 (193 CBSAs) Cluster: 3 (30 CBSAs)	• [p		
Time Time Cluster: 5 (88 CBSAs) Cluster: 12 (38 CBSAs)	•]		

Causal Inference


OAL: to evaluate the utility of targeted rning (TL) framework for establishing admap for optimally estimating causal ects and association measures from real orld data (RWD)

ETHOD: apply targeted minimum losssed estimation (TMLE) combined with in both randomized trials and complex servational settings

NDING:

TMLE + SL outperformed the propensity score (PS) matching and inverse probability weighting methods using parametric modeling

SL for estimating PS or missingness probability improved the overall performance of causal effect estimation in both PS matching and weighting analyses



Conclusion

Use of ML methods could improve performance of model predictions and causal effect estimation to better inform regulatory decision making.

These projects demonstrate the present utility and future potential of ML for regulatory science.